Protagonist Therapeutics, Inc. (PTGX)
Nasdaq: PTGX · Pharmaceutical Preparations · Newark, CA · filing with the SEC since 2006
Grade5.7
◀ Past 4.3● Present 7.6▶ Future 4.9
Who owns Protagonist Therapeutics, Inc.
As filed with the SECHolders of 5% or more
8
Blackrock, Inc. holds 15.2% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
8
report now, of 23 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 13.8% in Oct 17, 2025
Farallon Capital Management, L.L.C.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.00001 per share (the "Shares")
Dapice Joshua J.
SCHEDULE 13G/A · filed Feb 6, 2026 · Common Stock, par value $0.00001 per share (the "Shares") · 9.99% in Feb 10, 2025
RTW Investments, LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.00001 par value
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · 4.9% in May 12, 2026
Wellington Management Group LLP
SCHEDULE 13G · filed Feb 10, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Bvf Partners L P/il
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 5.2% in Jun 16, 2025
Deep Track Capital, LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.00001 · reported falling below 5%, from 5.29% in Apr 10, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 8.65% in Jan 30, 2026
What PTGX reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 25, 2026.
Insider tradesForm 4
39sales
0purchases
13sales on a scheduled plan
7people selling
$96.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Patel Dinesh V Ph D | President and CEO | 14 | $60.6M | 6 | 0 | $0 |
| Ali Asif | Chief Financial Officer | 7 | $15.6M | 2 | 0 | $0 |
| Giraudo Bryan | director | 4 | $5.9M | 0 | 0 | $0 |
| Waddill William D. | director | 6 | $5.6M | 5 | 0 | $0 |
| Molina Arturo Md | Chief Medical Officer | 6 | $4.5M | 0 | 0 | $0 |
| Selick Harold E | director | 1 | $2.5M | 0 | 0 | $0 |
| Williams Lewis T | director | 1 | $1.5M | 0 | 0 | $0 |